NFE2L2 and non-small cell lung carcinoma: In this prospective cohort study of patients with unresectable stage III NSCLC treated with CRT and durvalumab, high bTMB and PD-L1 ≥ 1% were associated with longer PFS, while ctDNA-detected mutations in STK11, KEAP1, or NFE2L2 were linked to shorter PFS.